4.4 Article

Differences in neutralizing antigenicity between laboratory and clinical isolates of HCoV-229E isolated in Japan in 2004-2008 depend on the S1 region sequence of the spike protein

Related references

Note: Only part of the references are listed.
Article Virology

Protease-Mediated Entry via the Endosome of Human Coronavirus 229E

Miyuki Kawase et al.

JOURNAL OF VIROLOGY (2009)

Article Microbiology

Human coronavirus NL63 and 229E seroconversion in children

Ronald Dijkman et al.

JOURNAL OF CLINICAL MICROBIOLOGY (2008)

Article Biochemistry & Molecular Biology

MEGA4: Molecular evolutionary genetics analysis (MEGA) software version 4.0

Koichiro Tamura et al.

MOLECULAR BIOLOGY AND EVOLUTION (2007)

Article Multidisciplinary Sciences

Protease-mediated enhancement of severe acute respiratory syndrome coronavirus infection

S Matsuyama et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)

Article Biotechnology & Applied Microbiology

Vesicular stomatitis virus pseudotyped with severe acute respiratory syndrome coronavirus spike protein

S Fukushi et al.

JOURNAL OF GENERAL VIROLOGY (2005)

Article Biochemistry & Molecular Biology

Identification of a new human coronavirus

L van der Hoek et al.

NATURE MEDICINE (2004)

Article Multidisciplinary Sciences

Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry

G Simmons et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)

Article Multidisciplinary Sciences

Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association

JH Sui et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)

Review Biochemistry & Molecular Biology

Severe acute respiratory syndrome

JSM Peiris et al.

NATURE MEDICINE (2004)

Article Biotechnology & Applied Microbiology

VSV-G pseudotyped lentiviral vector particles produced in human cells are inactivated by human serum

NJ DePolo et al.

MOLECULAR THERAPY (2000)